APVO SEC फाइलिंग - Aptevo Therapeutics Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	529900UTQOXOZBMZFN24
CIK	1671584

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aptevo Therapeutics Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

September 4, 2025	EX-99.1	Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX design to target prostate and multiple solid tumor cancers by Exhibit 99.1 Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived
September 4, 2025	8-K	FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 04, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commis
August 11, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commissio
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
August 11, 2025	EX-99.1	Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Mipletamig’s 85% frontline AML remission rate and favorable safety profile drive APVO’s differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific Exhibit 99.1 Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Mipletamig’s 85% frontline AML remission rate and favorable safety profile drive APVO’s differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates—mipletamig (AML), APVO442 (prostate cancer), and n
August 8, 2025	424B4	8,250,825 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-288959 8,250,825 Shares of Common Stock This prospectus relates to the offer and sale of up to 8,250,825 shares (the “shares”) of our common stock, par value $0.001 per share (“common stock”) by YA II PN, LTD. (“YA” or the “selling stockholder”), a Cayman Islands exempt limited partnership. The shares of common stock being offered by the sellin
July 25, 2025	S-1	As filed with the Securities and Exchange Commission on July 25, 2025 As filed with the Securities and Exchange Commission on July 25, 2025 Registration No.
July 25, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Registration Statement on Form S-1 (Form Type) APTEVO THERAPEUTICS INC.
July 24, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
July 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
July 1, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 30, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 23, 2025	EX-16.1	Letter of Moss Adams LLP to the Securities and Exchange Commission dated June 23, 2025. Exhibit 16.1 June 23, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by the Aptevo Therapeutics Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 23, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sinc
June 23, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 23, 2025	8-K	FORM 8-K Item 4.01 Changes in Registrant’s Certifying Accountant. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 20, 2025	EX-4.2	Pre-funded Warrant, dated June 20, 2025 EXHIBIT 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he
June 20, 2025	EX-10.2	Securities Purchase Agreement, dated June 18, 2025, between the Company and the purchasers party thereto. EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 18, 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition
June 20, 2025	EX-10.1	Placement Agency Agreement, dated June 18, 2025, between the Company and Roth Capital Partners. EXHIBIT 10.1 PLACEMENT AGENCY AGREEMENT June 18 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $8,011,250 of registered securities (the “Securities”)
June 20, 2025	EX-99.4	Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo’s expansion from hematologic to solid tumors New c EXHIBIT 99.4 Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo’s expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo’s tumor-directed CD3 suite SEATTLE, W
June 20, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 20, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 20, 2025	424B4	2,105,000 Shares of Common Stock 360,000 Pre-Funded Warrants to Purchase 360,000 Shares of Common Stock 12,325,000 Common Warrants to Purchase 12,325,000 Shares of Common Stock 12,685,000 Shares of Common Stock underlying the Pre-Funded Warrants and Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-288061 and 333-288134 2,105,000 Shares of Common Stock 360,000 Pre-Funded Warrants to Purchase 360,000 Shares of Common Stock 12,325,000 Common Warrants to Purchase 12,325,000 Shares of Common Stock 12,685,000 Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants This is a registered direct offering of 2,105,000 shares
June 20, 2025	EX-99.1	Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.1 Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA – June 18, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that it has entered into securities pur
June 20, 2025	EX-4.1	Common Warrant, dated June 20, 2025 EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: June 20, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approva
June 20, 2025	424B5	Up to $8,037,381 PROSPECTUS SUPPLEMENT (To Prospectus dated February 26, 2025) Filed Pursuant to Rule 424(b)(5) Registration No.
June 20, 2025	EX-99.3	Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML 85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting EXHIBIT 99.3 Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML 85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains strong Evidence mounts for mipletamig as a potentially transformatio
June 20, 2025	EX-99.2	Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.2 Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA – June 20, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previousl
June 18, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
June 18, 2025	S-1MEF	As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No.
June 17, 2025	EX-10.1	Standby Equity Purchase Agreement, Dated June 16, 2025, between the Company and YA II PN, Ltd. Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of June 16, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and APTEVO THERAPEUTICS INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individ
June 17, 2025	8-K	FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
June 16, 2025	EX-10.59	Form of Securities Purchase Agreement EXHIBIT 10.59 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
June 16, 2025	S-1	As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No.
June 16, 2025	EX-4.21	Form of Common Warrant EXHIBIT 4.21 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as
June 16, 2025	CORRESP	June 16, 2025 June 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 16, 2025	EX-4.20	Form of Pre-Funded Warrant EXHIBIT 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
June 16, 2025	EX-10.60	Form of Placement Agency Agreement EXHIBIT 10.60 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Compan
June 16, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
May 30, 2025	EX-4.20	(Signature Page Follows) EXHIBIT 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
May 30, 2025	DRS	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. § 200.83 CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. § 200.83 As confidentially submitted to the Securities and Exchange Commission on May 30, 2025 under the Securities Act of 1933, as amended. This draft registration statement has not been publicly filed with the Securities and Exchange Commission, and all information herein is strictly confidential Registration No. 333- UNITED STATES SECURITIE
May 30, 2025	EX-10.60	PLACEMENT AGENCY AGREEMENT EXHIBIT 10.60 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Compan
May 30, 2025	EX-4.21	(Signature Page Follows) EXHIBIT 4.21 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as
May 30, 2025	EX-10.59	“Acquiring Person” shall have the meaning ascribed to such term in Section 4.5. (a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: Exhibit 10.59 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
May 28, 2025	424B3	Up to 3,529,420 Shares of Common Stock Issuable Upon the Exercise of Common Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-287244 PROSPECTUS Up to 3,529,420 Shares of Common Stock Issuable Upon the Exercise of Common Warrants This prospectus relates to the resale from time to time by certain selling stockholders named herein (the “Holders”) of up to 3,529,420 shares of Common Stock, par value $0.001 per share (“Common Stock”), of Aptevo Therapeutics Inc. (“Company,
May 23, 2025	EX-3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APTEVO THERAPEUTICS INC. APTEVO THERAPEUTICS Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: First: The name of this corporation is Aptevo Therapeutics Inc. (the “Company”). Second: The date on which the Company’s Certificate of Incorpora
May 23, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission F
May 22, 2025	424B5	Up to $3,015,515 PROSPECTUS SUPPLEMENT (To Prospectus dated February 26, 2025) Filed Pursuant to Rule 424(b)(5) Registration No.
May 22, 2025	EX-99.1	Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan Exhibit 99.1 Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan SEATTLE, WA / ACCESSWIRE / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ: APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (“Common Stock”), at a ratio of 1-for-20 (the "Reverse
May 22, 2025	8-K	FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission F
May 21, 2025	CORRESP	May 21, 2025 May 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
May 15, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission F
May 15, 2025	EX-99.1	APTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON MIPLETAMIG 9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform stand Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON MIPLETAMIG 9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in front
May 13, 2025	RW	May 13, 2025 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
May 13, 2025	S-1	As filed with the Securities and Exchange Commission on May 13, 2025 As filed with the Securities and Exchange Commission on May 13, 2025 Registration No.
May 13, 2025	RW	May 13, 2025 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
May 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) APTEVO THERAPEUTICS INC.
May 2, 2025	S-3	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) APTEVO THERAPEUTICS INC.
April 29, 2025	424B5	Up to $3,167,548 PROSPECTUS SUPPLEMENT (To Prospectus dated February 26, 2025) Filed Pursuant to Rule 424(b)(5) Registration No.
April 29, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
April 28, 2025	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
April 28, 2025	EX-1.1	Sales Agreement, dated as of April 28, 2025, by and between Aptevo Therapeutics Inc. and Roth Capital Partners, LLC. Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT April 28, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Aptevo Therapeutics Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Manager”) as follows: 1. Definitions. The terms that follow
April 28, 2025	424B4	Roth Capital Partners The date of this prospectus supplement is April 28, 2025. Filed Pursuant to Rule 424(b)(5) Registration No. 333-284969 PROSPECTUS SUPPLEMENT (to the Prospectus dated February 14, 2025) $2,959,952 We have entered into an At The Market Offering Agreement (the "Sales Agreement"), with Roth Capital Partners ("Roth"), dated April 28, 2025, relating to shares of our common stock, $0.001 par value per share ("common stock"), offered by this prospectus supplemen
April 25, 2025	DEF 14A	QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Proposal 1 APPROVAL OF THE STOCK ISSUANCE AND WARRANT PROPOSAL Proposal 2 REVERSE STOCK SPLIT PROPOSAL Proposal 3 AUTHORIZATION TO ADJOURN THE SPECIAL MEETING Security Ownership of Certain UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 22, 2025	EX-99.1	Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SEATTLE, WA – April 21, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced today
April 22, 2025	EX-99.2	Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.2 Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SEATTLE, WA – April 22, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform techn
April 22, 2025	424B4	APTEVO THERAPEUTICS INC. 2,324,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284969 PROSPECTUS SUPPLEMENT (to the Prospectus dated February 14, 2025) APTEVO THERAPEUTICS INC. 2,324,000 Shares of Common Stock We are offering directly to investors 2,324,000 shares (the "shares") of our common stock, $0.001 par value per share (“common stock”), in a registered direct offering pursuant to this prospectus supplement and the
April 22, 2025	EX-10.2	Form of Securities Purchase Agreement, dated April 21, 2025, between the Company and the purchasers party thereto. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 21, 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio
April 22, 2025	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
April 22, 2025	EX-10.1	Form of Placement Agency Agreement, dated April 21, 2025, between the Company and Roth Capital Partners. Exhibit 10.1 PLACEMENT AGENCY AGREEMENT April 21, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,003,288 of registered shares (the “Shares”) of th
April 10, 2025	PRE 14A	QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Proposal 1 APPROVAL OF THE STOCK ISSUANCE AND WARRANT PROPOSAL Proposal 2 REVERSE STOCK SPLIT PROPOSAL Proposal 3 AUTHORIZATION TO ADJOURN THE SPECIAL MEETING Security Ownership of Certain UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 4, 2025	EX-10.1	Form of Placement Agency Agreement, dated April 3, 2025, between the Company and Roth Capital Partners. Exhibit 10.1 PLACEMENT AGENCY AGREEMENT April 3, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,100,004.90 of registered securities (the “Securiti
April 4, 2025	EX-4.1	Form of Common Warrant, dated April 4, 2025 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 03, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
April 4, 2025	EX-99.1	Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SEATTLE, WA – April 3, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platfor
April 4, 2025	EX-4.2	Form of Amended Common Warrant, dated April 4, 2025 (originally entered into on December 12, 2024), between the Company and certain warrant holders Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2025	EX-10.2	Form of Securities Purchase Agreement, dated April 3, 2025, between the Company and the purchasers party thereto. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 3, 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition
April 4, 2025	EX-99.2	Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Exhibit 99.2 Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SEATTLE, WA – April 4, 2025 – Aptevo Therapeutics Inc. (Nasdaq: APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™
April 4, 2025	424B4	APTEVO THERAPEUTICS INC. 1,764,710 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284969 PROSPECTUS SUPPLEMENT (to the Prospectus dated February 14, 2025) APTEVO THERAPEUTICS INC. 1,764,710 Shares of Common Stock We are offering directly to investors 1,764,710 shares of our common stock, $0.001 par value per share (“common stock”), in a registered direct offering pursuant to this prospectus supplement and the accompanying pr
April 1, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
April 1, 2025	S-1/A	As filed with the Securities and Exchange Commission on March 31, 2025. As filed with the Securities and Exchange Commission on March 31, 2025. Registration No. 333-285476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpor
March 27, 2025	EX-4.13	Form of Series B Warrant SERIES B COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval
March 27, 2025	S-1/A	As filed with the Securities and Exchange Commission on March 27, 2025. As filed with the Securities and Exchange Commission on March 27, 2025. Registration No. 333-285476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpor
March 27, 2025	EX-4.13	Form of Series B Warrant SERIES B COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval
March 27, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
March 27, 2025	S-1/A	As filed with the Securities and Exchange Commission on March 27, 2025. As filed with the Securities and Exchange Commission on March 27, 2025. Registration No. 333-285476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpor
March 27, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
March 25, 2025	S-1/A	As filed with the Securities and Exchange Commission on March 24, 2025. As filed with the Securities and Exchange Commission on March 24, 2025. Registration No. 333-285476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpor
March 25, 2025	EX-4.13	Form of Series B Warrant Exhibit 4.13 SERIES B COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockho
March 25, 2025	EX-4.11	Form of Pre-Funded Warrant EXHIBIT 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
March 25, 2025	EX-10.56	Form of Placement Agency Agreement Exhibit 10.56 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Compan
March 25, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
March 25, 2025	EX-4.12	Form of Series A Warrant Exhibit 4.12 SERIES A COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockho
March 25, 2025	EX-10.55	Form of Securities Purchase Agreement Exhibit 10.55 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
March 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
March 20, 2025	EX-99.2	RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Co Exhibit 99.2 RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in t
March 20, 2025	EX-99.1	20, March 2025 \| Nasdaq: APVO 20, March 2025 \| Nasdaq: APVO Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
March 3, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
March 3, 2025	EX-10.56	Form of Placement Agency Agreement Exhibit 10.56 PLACEMENT AGENCY AGREEMENT , 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Compan
March 3, 2025	EX-4.11	Form of Pre-Funded Warrant EXHIBIT 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
March 3, 2025	EX-10.55	Form of Securities Purchase Agreement Exhibit 10.55 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
March 3, 2025	S-1	As filed with the Securities and Exchange Commission on February 28, 2025. As filed with the Securities and Exchange Commission on February 28, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization
March 3, 2025	EX-4.12	Form of Series A Warrant Exhibit 4.12 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the [Stockholder Approval (as
February 24, 2025	CORRESP	February 24, 2025 February 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
February 14, 2025	EX-99.1	APTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE 100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE 100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Ca
February 14, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Aptevo Therapeutics Inc.
February 14, 2025	EX-4.15	Form of Pre-Funded Warrant Exhibit 4.15 APTEVO THERAPEUTICS INC. WARRANT TO PURCHASE COMMON STOCK Warrant No. Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such
February 14, 2025	S-3	As filed with the Securities and Exchange Commission on February 14, 2025 As filed with the Securities and Exchange Commission on February 14, 2025 Registration No.
February 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37746 APTEVO THERAPEU
February 14, 2025	EX-97	APTEVO THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Adopted as of April 17, 2023 Exhibit 97 APTEVO THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Adopted as of April 17, 2023 Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former
February 14, 2025	EX-4.12	Form of Certificate of Designation of Preferred Stock Exhibit 4.12 CERTIFICATE OF DESIGNATION OF SERIES [] PREFERRED STOCK OF APTEVO THERAPEUTICS inc. (Pursuant to Section 151 of the Delaware General Corporation Law) Aptevo Therapeutics Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of the Delaware, as amended (the “DGCL”), hereby certifies that, pursuant to the authority granted by Artic
February 14, 2025	EX-19.1	Insider trading policies and procedures Exhibit 19.1 1.0 PURPOSE 1.1 The federal securities laws prohibits any member of the Board of Directors (a “Director”) or employee of Aptevo Therapeutics Inc. (together with its subsidiaries, the “Company”) from purchasing or selling Company securities on the basis of material nonpublic information concerning the Company, or from tipping material nonpublic information to others. These laws impose
February 14, 2025	EX-4.16	Form of Rights Certificate Exhibit 4.16 FORM OF RIGHTS CERTIFICATE Certificate No. R- Rights NOT EXERCISABLE AFTER 5:00 P.M., NEW YORK CITY TIME, [] UNLESS THE RIGHTS ARE EARLIER REDEEMED OR EXCHANGED. THE RIGHTS ARE SUBJECT TO REDEMPTION AT $[] PER RIGHT AND TO EXCHANGE, IN EACH CASE, AT THE OPTION OF THE COMPANY, ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. THE RIGHTS EVIDENCED BY THIS CERTIFICATE SHALL NOT BE EXERCISA
February 14, 2025	EX-4.14	Form of Warrant Exhibit 4.14 APTEVO THERAPEUTICS INC. WARRANT TO PURCHASE COMMON STOCK Warrant No. Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such
February 14, 2025	EX-4.13	Form of Indenture Exhibit 4.13 APTEVO THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 S
February 14, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
February 14, 2025	EX-21.1	LIST OF SUBSIDIARIES EXHIBIT 21.1 LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Aptevo Research and Development LLC Delaware
February 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
February 11, 2025	EX-99.1	CONFIDENTIAL 11, February 2025 \| Nasdaq: APVO CONFIDENTIAL 11, February 2025 \| Nasdaq: APVO Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
January 2, 2025	CORRESP	December 31, 2024 December 31, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
December 20, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) APTEVO THERAPEUTICS INC.
December 20, 2024	S-3	As filed with the Securities and Exchange Commission on December 20, 2024 As filed with the Securities and Exchange Commission on December 20, 2024 Registration No.
December 12, 2024	EX-4.1	Form of Common Warrant, dated December 12, 2024 EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 12, 2024	EX-99.1	100% of Patients Achieve Remission within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongo Exhibit 99.1 100% of Patients Achieve Remission within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing Seattle, Washington, December 12, 2024 - Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO
December 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
December 12, 2024	EX-10.1	Warrant Inducement Agreement, by and between the Company and each Holder. Exhibit 10.1 Aptevo Therapeutics inc. December 12, 2024 Holder of the (i) September 2024 Common Stock Purchase Warrants, (ii) June 2024 Common Stock Purchase Warrants, (iii) April 2024 Common Stock Purchase Warrants, (iv) November 2023 Common Stock Purchase Warrants and (v) August 2023 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Aptev
December 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
December 4, 2024	EX-99.1	Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects Powered by Aptevo’s proprietary ADAPTIR-FLEX platform, antibody innovation targeting difficult-to-treat cancers Exhibit 99.1 Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects Powered by Aptevo’s proprietary ADAPTIR-FLEX platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA – December 4, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel
December 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
December 3, 2024	EX-3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APTEVO THERAPEUTICS INC. APTEVO THERAPEUTICS Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: First: The name of this corporation is Aptevo Therapeutics Inc. (the “Company”). Second: The date on which the Company’s Certificate of Incorpora
December 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 26, 2024	EX-99.1	Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation Aptevo’s Peter Pavlik, PhD, to chair a session on “Bi and Multispecific Biologics” and will also give talk titled “Modular M Exhibit 99.1 Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation Aptevo’s Peter Pavlik, PhD, to chair a session on “Bi and Multispecific Biologics” and will also give talk titled “Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform” at Cambridge Healthcare Institute’s, Pep Talk 2025 Sea
November 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 22, 2024	EX-99.1	Aptevo Highlights the Potential of the Company’s Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm Developing innovative bispecific antibodies for monot Exhibit 99.1 Aptevo Highlights the Potential of the Company’s Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA—November 22, 2024—Aptevo Therapeutics (
November 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 20, 2024	EX-99.1	First Patient Dosed in Aptevo’s Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies Potential to redefine frontline AML treatment Exhibit 99.1 First Patient Dosed in Aptevo’s Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy f
November 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 14, 2024	SC 13G/A	APVO / Aptevo Therapeutics Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-apvo093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aptevo Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03835L306 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch
November 8, 2024	SC 13G	APVO / Aptevo Therapeutics Inc. / Hudson Bay Capital Management LP - APVO 13G Passive Investment SC 13G 1 apvo13g.htm APVO 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Aptevo Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03835L306 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
November 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 7, 2024	EX-99.1	APTEVO THERAPEUTICS REPORTS 3Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, “RAINIER,” in Frontline Acute Myeloid Leukemia, Informed by Pos Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 3Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, “RAINIER,” in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Societ
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
November 4, 2024	EX-4.1	Amendment No. 4 to Rights Agreement, dated as of November 1, 2024, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent Exhibit 4.1 APTEVO THERAPEUTICS INC. AMENDMENT NO. 4 TO RIGHTS AGREEMENT This Amendment No. 4 (this “Amendment”), dated as of November 1, 2024, to the Rights Agreement, dated November 8, 2020, as amended (the “Rights Agreement”), between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), Broadridge Financial Solutions, LLC., as rights agent (the “Rights Agent”). WHEREAS, the Company
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
October 25, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commissi
October 3, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
September 23, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
September 18, 2024	EX-10.4	Form of Amended Series A-2 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. Exhibit 10.4 SERIES A-2 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 Previously Amended and Restated Date: July 1, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limita
September 18, 2024	EX-10.6	Form of Amended Series B-2 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. Exhibit 10.6 SERIES B-2 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 Previously Amended and Restated Date: July 1, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limita
September 18, 2024	EX-10.5	Form of Amended Series B-1 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. Exhibit 10.5 SERIES B-1 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 Previously Amended and Restated Date: July 1, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limita
September 18, 2024	EX-10.8	Form of Amended Warrant, dated September 18, 2024 (originally entered into on July 1, 2024), between the Company and certain warrant holders. Exhibit 10.8 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Original Issuance Date: July 1, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at
September 18, 2024	EX-4.1	Form of Common Warrant, dated September 18, 2024 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as d
September 18, 2024	EX-10.1	Placement Agency Agreement, dated September 16, 2024, between the Company and Roth Capital Partners. Exhibit 10.1 PLACEMENT AGENCY AGREEMENT September 16. 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $3,000,000.30 of registered securities (the “Sec
September 18, 2024	EX-10.7	Form of Amended Warrant, dated September 18, 2024 (originally entered into on April 15, 2024), between the Company and certain warrant holders. Exhibit 10.7 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Original Issue Date: April 15, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a
September 18, 2024	EX-99.1	Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA – September 16, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securit
September 18, 2024	EX-99.2	Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.2 Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA – September 18, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its pr
September 18, 2024	EX-10.2	Securities Purchase Agreement, dated September 16, 2024, between the Company and the purchasers party thereto. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 16, 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and cond
September 18, 2024	EX-10.3	Form of Amended Series A-1 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. Exhibit 10.3 SERIES A-1 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 Previously Amended and Restated Date: July 1, 2024 Amended and Restated Date: September 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limita
September 18, 2024	EX-4.2	Pre-funded Warrant, dated September 18, 2024. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he
September 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commis
September 17, 2024	424B4	4,020,000 Shares of Common Stock 5,070,910 Pre-Funded Warrants to Purchase 5,070,910 Shares of Common Stock 18,181,820 Common Warrants to Purchase 18,181,820 Shares of Common Stock 23,252,730 Shares of Common Stock underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(4) Registration No. 333-281892 4,020,000 Shares of Common Stock 5,070,910 Pre-Funded Warrants to Purchase 5,070,910 Shares of Common Stock 18,181,820 Common Warrants to Purchase 18,181,820 Shares of Common Stock 23,252,730 Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants This is a reasonable best efforts offering of up to 4,020,000 shares
September 16, 2024	EX-99.1	Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Early Data Indicate Clinical Activity in Patients with Multiple Solid Exhibit 99.1 Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrated in Breast Cancer Patient Favorable Pharmacokinetics, Safety and Tol
September 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commis
September 11, 2024	CORRESP	Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 September 11, 2024 Securities and Exchange Commission 100 F Street, N.
September 11, 2024	CORRESP	September 11, 2024 September 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
August 30, 2024	EX-10.49	PLACEMENT AGENCY AGREEMENT EXHIBIT 10.49 PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Compan
August 30, 2024	EX-4.17	Form of Pre-Funded Warrant EXHIBIT 4.17 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
August 30, 2024	EX-10.48	SECURITIES PURCHASE AGREEMENT EXHIBIT 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
August 30, 2024	EX-4.18	Form of Common Warrant EXHIBIT 4.18 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as
August 30, 2024	S-1	As filed with the Securities and Exchange Commission on August 30, 2024. As filed with the Securities and Exchange Commission on August 30, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization)
August 30, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
August 8, 2024	EX-99.1	APTEVO THERAPEUTICS REPORTS 2Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE SEATTLE, WA – August 8, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended Marc
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commissio
August 7, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commissio
July 15, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
July 12, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aptevo Therapeutics Inc.
July 12, 2024	S-8	As filed with the U.S. Securities and Exchange Commission on July 12, 2024 As filed with the U.S. Securities and Exchange Commission on July 12, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aptevo Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 81-1567056 (State or other jurisdiction of incorporation or organization) (I.
July 3, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
July 1, 2024	EX-10.5	Form of Amended Series A-1 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.5 SERIES A-1 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the
July 1, 2024	EX-4.1	Form of Common Warrant, dated July 1, 2024 EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval
July 1, 2024	EX-10.1	Placement Agency Agreement dated June 28, 2024, between the Company and Roth Capital Partners. EXHIBIT 10.1 PLACEMENT AGENCY AGREEMENT June 28, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,750,000.09 of registered securities (the “Securiti
July 1, 2024	EX-10.3	Form of Amended Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.3 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Original Issue Date: April 15, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockhol
July 1, 2024	EX-99.1	Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.1 Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA / ACCESSWIRE / June 28, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into
July 1, 2024	EX-4.2	Pre-funded Warrant, dated July 1, 2024 EXHIBIT 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he
July 1, 2024	EX-10.2	Securities Purchase Agreement, dated June 28, 2024, between the Company and the purchasers party thereto. EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition
July 1, 2024	EX-99.2	Aptevo Therapeutics Announces Closing of $2.75 Million Offering EXHIBIT 99.2 Aptevo Therapeutics Announces Closing of $2.75 Million Offering SEATTLE, WA – July 1, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806
July 1, 2024	EX-10.4	Form of Amended Series A Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.4 SERIES A COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: August 4, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the date
July 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
July 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
July 1, 2024	EX-10.7	Form of Amended Series B-1 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.7 SERIES B-1 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: Original Issue Date: November 9, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the
July 1, 2024	EX-10.6	Form of Amended Series A-2 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.6 SERIES A-2 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: [] Original Issue Date: November [], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or aft
July 1, 2024	EX-10.8	Form of Amended Series B-2 Common Warrant, dated as of July 1, 2024, between the Company and certain warrant holders. EXHIBIT 10.8 SERIES B-2 COMMON STOCK PURCHASE WARRANT APTEVO THERAPEUTICS INC. Warrant Shares: [] Original Issue Date: November 9, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or afte
June 28, 2024	424B4	3,621,460 Shares of Common Stock 1,718,346 Pre-Funded Warrants to Purchase 1,718,346 Shares of Common Stock 10,679,612 Common Warrants to Purchase 10,679,612 Shares of Common Stock 12,397,958 Shares of Common Stock underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(4) Registration No. 333-280226 3,621,460 Shares of Common Stock 1,718,346 Pre-Funded Warrants to Purchase 1,718,346 Shares of Common Stock 10,679,612 Common Warrants to Purchase 10,679,612 Shares of Common Stock 12,397,958 Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants This is a reasonable best efforts offering of up to 3,621,460 shares
June 26, 2024	S-1/A	As filed with the Securities and Exchange Commission on June 26, 2024. As filed with the Securities and Exchange Commission on June 26, 2024. Registration No. 333-280226 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpora
June 25, 2024	CORRESP	June 25, 2024 June 25, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 14, 2024	EX-4.22	Form of Placement Agency Agreement EXHIBIT 4.22 PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the Company
June 14, 2024	EX-4.19	Form of Pre-Funded Warrant EXHIBIT 4.19 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
June 14, 2024	S-1	As filed with the Securities and Exchange Commission on June 14, 2024. As filed with the Securities and Exchange Commission on June 14, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization) (P
June 14, 2024	EX-4.20	Form of Common Warrant EXHIBIT 4.20 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Issue Date: , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Stockholder Approval (as
June 14, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
June 14, 2024	EX-4.21	Form of Securities Purchase Agreement EXHIBIT 4.21 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set f
June 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission F
May 8, 2024	EX-99.1	APTEVO THERAPEUTICS REPORTS 1Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 1Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new advers
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
April 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
April 15, 2024	EX-10.1	Placement Agent Agreement, dated April 10, 2024, between the Company and Roth Capital Partners Exhibit 10.1 PLACEMENT AGENCY AGREEMENT April 10, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $4,590,000 of registered securities (the “Securities
April 15, 2024	EX-10.2	Securities Purchase Agreement, dated April 10, 2024, between the Company and the purchasers party thereto. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio
April 15, 2024	EX-4.2	Pre-funded Warrant, dated April 15, 2024 Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: April 15, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the
April 15, 2024	EX-99.1	Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering Exhibit 99.1 Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering SEATTLE, WA – April 11, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the pricing of a public offering of (i) 3,400,000 shares o
April 15, 2024	EX-99.2	Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering Exhibit 99.2 Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering SEATTLE, WA – April 15, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced public offering of
April 15, 2024	EX-4.1	Form of Common Warrant, dated April 15, 2024 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: April 15, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 15, 2024 (the “Init
April 12, 2024	424B4	926,666 Shares of Common Stock 2,473,334 Pre-funded Warrants to Purchase 2,473,334 Shares of Common Stock 6,800,000 Common Warrants to Purchase 6,800,000 Shares of Common Stock 9,273,334 Shares of Common Stock underlying the Pre-funded Warrants and C Filed Pursuant to Rule 424(b)(4) Registration No. 333-278103 926,666 Shares of Common Stock 2,473,334 Pre-funded Warrants to Purchase 2,473,334 Shares of Common Stock 6,800,000 Common Warrants to Purchase 6,800,000 Shares of Common Stock 9,273,334 Shares of Common Stock underlying the Pre-funded Warrants and Common Warrants This is a reasonable best efforts public offering of up to 926,666 shares
April 9, 2024	S-1/A	As filed with the Securities and Exchange Commission on April 9, 2024. As filed with the Securities and Exchange Commission on April 9, 2024. Registration No. 333-278103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpora
April 8, 2024	CORRESP	Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 April 8, 2024 Securities and Exchange Commission 100 F Street, N.
April 8, 2024	CORRESP	Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 April 8, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama Ms. Laura Crotty Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1, as amended File No. 333-278103 Dear
March 29, 2024	S-1/A	As filed with the Securities and Exchange Commission on March 29, 2024. As filed with the Securities and Exchange Commission on March 29, 2024. Registration No. 333-278103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorpor
March 29, 2024	CORRESP	************************* March 29, 2024 Via EDGAR Submission Ms. Doris Stacey Gama Ms. Laura Crotty U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed March 20, 2024 File No. 333-278103 Dear Ms. Gama and Ms. Crotty: On behalf of our client, Aptevo Therapeutics Inc., a
March 20, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aptevo Therapeutics Inc.
March 20, 2024	EX-4.20	Form of Common Warrant Exhibit 4.20 FORM OF COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 CUSIP: ISIN: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (the “Initi
March 20, 2024	S-1	As filed with the Securities and Exchange Commission on March 20, 2024. As filed with the Securities and Exchange Commission on March 20, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization) (
March 20, 2024	EX-4.21	Form of Securities Purchase Agreement Exhibit 4.21 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio
March 20, 2024	EX-4.19	Form of Pre-Funded Warrant Exhibit 4.19 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT aptevo therapeutics inc. Warrant Shares: Initial Exercise Date: , 2024 CUSIP: ISIN: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
March 20, 2024	EX-4.22	Form of Placement Agency Agreement Exhibit 4.22 FORM OF PLACEMENT AGENCY AGREEMENT , 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities (the “Securities”) of the
March 7, 2024	EX-99.1	Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 Initial interim data show favorable drug exposure and confirm ALG.AP Exhibit 99.1 Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activity Early promising signs of clinical activity in heavily pretreated patients Dose-escalation trial data on track f
March 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
March 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
March 5, 2024	EX-97	Compensation Recovery Policy Exhibit 97 APTEVO THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Adopted as of April 17, 2023 Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former
March 5, 2024	EX-3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF APTEVO THERAPEUTICS INC. APTEVO THERAPEUTICS INC., a corporation organized and existing under the laws of the State of Delaware, herby certifies as follows: First: The name of this corporation is Aptevo Therapeutics Inc. (the “Company”). Second: The date on which the Company’s Certificate of Incorporation was orig
March 5, 2024	EX-21.1	Subsidiaries of Aptevo Therapeutics Inc. EXHIBIT 21.1 LIST OF SUBSIDIARIES Name of Subsidiary Jurisdiction of Incorporation or Organization Aptevo Research and Development LLC Delaware
March 5, 2024	EX-99.1	APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phas Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA – March 5, 2024 – Ap
March 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commission
March 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37746 APTEVO THERAPEU
February 14, 2024	SC 13G	APVO / Aptevo Therapeutics Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-apvo123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aptevo Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03835L207 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the
February 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
January 30, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) mscho UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 16, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
December 22, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
December 12, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 29, 2023	CORRESP	November 29, 2023 November 29, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
November 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) APTEVO THERAPEUTICS INC.
November 22, 2023	S-3	As filed with the Securities and Exchange Commission on November 22, 2023 As filed with the Securities and Exchange Commission on November 22, 2023 Registration No.
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 APTEVO THERAPEUTICS INC.
November 14, 2023	EX-99.1	APTEVO THERAPEUTICS REPORTS 3Q23 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE The Company’s ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/ Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 3Q23 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE The Company’s ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ongoing Extended Cash Runway with $7 Million in Funding and Potential for Additional $9.2 Million SEATTLE, W
November 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 APTEVO THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37746 81-1567056 (State or Other Jurisdiction of Incorporation) (Commiss

APVO / Aptevo Therapeutics Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)

Other Listings